Our Reports
Automotive ReportsElectronics & SemiconductorTelecom & ITTechnology & ITConsumer GoodsHealthcareFood & BeveragesChemical
Our Links
About UsContact UsPress ReleaseNewsOur Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Europe Erythropoietin Drugs Market By Drug Class (Biologics and Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others), By Application (Renal Diseases, Cancer, Hematology and Neurology), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Published Date : 24-Jun-2021

Pages: 80

Formats: PDF

The Europe Erythropoietin Drugs Market would witness market growth of 11.5% CAGR during the forecast period (2021-2027).

The market for Erythropoietin (EPO) Drugs is expected to grow in the forecast period. It is due to the increasing number of patients who are suffering from anaemia. The favourable reimbursements by the medical insurance companies as well as government and increasing commercialization of EPO drugs, and increasing occurrence of Chronic Kidney Diseases are some of the catalysts for the growth & demand for erythropoietin drugs.

Furthermore, the increasing prevalence of anaemic conditions due to end-stage renal disease treatment, chemotherapy in cancer, and antiretroviral treatment (ART) is the main factor that is likely to drive the growth of the erythropoietin market. Therefore, the number of treatment cycles for chemotherapy and rising incidences of end-stage renal diseases requiring dialysis have augmented demand for EPO.

Arterial hypertension, iron deficiency, and influenza-like syndrome, and a longer duration of EPO treatment (4-6 weeks) are some of the side effects of erythropoietin drugs. This aspect is expected to restrain the growth of the erythropoietin drug market. Although, the trends of commercialization for erythropoietin drugs are increasing, available reimbursements and favourable regulations by the government are leading to increased demand for erythropoietin drugs. Furthermore, increasing awareness among people about the benefits of EPO therapeutics is expected to boost the growth of the erythropoietin drugs market.

Erythropoietin Drugs Market is expected to grow at a significant rate in Europe. Erythropoietin is a hormone produced by the kidney and induces the formation of red blood cells in the bone marrow cells. They are used for the treatment of anaemia, HIV, and Cancer. Nowadays, due to advancements in recombinant DNA technology, several synthetic forms of erythropoietin are available in the market.

The increased occurrence of anaemia and favorable commercialization of EPO drugs in Europe is likely to boost the demand for Erythropoietin Drugs over the forecast period. The favourable reimbursement policies by the government are further driving the market growth. The availability of biosimilars in the market is expected to increase further during the forecast period.

The Germany market dominated the Europe Darbepoetin-alfa Market by Country in 2020, thereby, achieving a market value of $283.4 million by 2027. The UK market is exhibiting a CAGR of 11.2% during (2021 - 2027). Additionally, The France market is anticipated to witness a CAGR of 13.7% during (2021 - 2027).

Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Global Erythropoietin Drugs Market Size will Hit $20.2 Billion by 2027, at a CAGR of 11.8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Drug Class

  • Biologics
  • Biosimilars

By Product

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • others

By Application

  • Renal Diseases
  • Cancer
  • Hematology
  • Neurology

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • Johnson and Johnson
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Biocon Limited
  • Intas Pharmaceutical Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • LG Corporation (LG Life Sciences Ltd.)
  • Celltrion, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Erythropoietin Drugs Market, by Drug Class
1.4.2 Europe Erythropoietin Drugs Market, by Product
1.4.3 Europe Erythropoietin Drugs Market, by Application
1.4.4 Europe Erythropoietin Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Europe Erythropoietin Drugs Market by Drug Class
3.1 Europe Biologics Market by Country
3.2 Europe Biosimilars Market by Country

Chapter 4. Europe Erythropoietin Drugs Market by Product
4.1 Europe Epoetin-alfa Market by Country
4.2 Europe Epoetin-beta Market by Country
4.3 Europe Darbepoetin-alfa Market by Country
4.4 Europe Other Product Market by Country

Chapter 5. Europe Erythropoietin Drugs Market by Application
5.1 Europe Renal Diseases Market by Country
5.2 Europe Cancer Market by Country
5.3 Europe Hematology Market by Country
5.4 Europe Neurology Market by Country

Chapter 6. Europe Erythropoietin Drugs Market by Country
6.1 Germany Erythropoietin Drugs Market
6.1.1 Germany Erythropoietin Drugs Market by Drug Class
6.1.2 Germany Erythropoietin Drugs Market by Product
6.1.3 Germany Erythropoietin Drugs Market by Application
6.2 UK Erythropoietin Drugs Market
6.2.1 UK Erythropoietin Drugs Market by Drug Class
6.2.2 UK Erythropoietin Drugs Market by Product
6.2.3 UK Erythropoietin Drugs Market by Application
6.3 France Erythropoietin Drugs Market
6.3.1 France Erythropoietin Drugs Market by Drug Class
6.3.2 France Erythropoietin Drugs Market by Product
6.3.3 France Erythropoietin Drugs Market by Application
6.4 Russia Erythropoietin Drugs Market
6.4.1 Russia Erythropoietin Drugs Market by Drug Class
6.4.2 Russia Erythropoietin Drugs Market by Product
6.4.3 Russia Erythropoietin Drugs Market by Application
6.5 Spain Erythropoietin Drugs Market
6.5.1 Spain Erythropoietin Drugs Market by Drug Class
6.5.2 Spain Erythropoietin Drugs Market by Product
6.5.3 Spain Erythropoietin Drugs Market by Application
6.6 Italy Erythropoietin Drugs Market
6.6.1 Italy Erythropoietin Drugs Market by Drug Class
6.6.2 Italy Erythropoietin Drugs Market by Product
6.6.3 Italy Erythropoietin Drugs Market by Application
6.7 Rest of Europe Erythropoietin Drugs Market
6.7.1 Rest of Europe Erythropoietin Drugs Market by Drug Class
6.7.2 Rest of Europe Erythropoietin Drugs Market by Product
6.7.3 Rest of Europe Erythropoietin Drugs Market by Application

Chapter 7. Company Profiles
7.1 Johnson and Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Amgen, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 F. Hoffmann-La Roche Ltd.
7.4.1 Company Overview
7.4.1 Financial Analysis
7.4.2 Segmental and Regional Analysis
7.4.3 Research & Development Expense
7.5 Biocon Limited
7.5.1 Company Overview
7.6 Intas Pharmaceutical Ltd.
7.6.1 Company Overview
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.8 Dr. Reddy’s Laboratories Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 LG Corporation (LG Life Sciences Ltd.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.10. Celltrion, Inc.
7.10.1 Company Overview
TABLE 1 Europe Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 2 Europe Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 3 Europe Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 4 Europe Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 5 Europe Biologics Market by Country, 2017 - 2020, USD Million
TABLE 6 Europe Biologics Market by Country, 2021 - 2027, USD Million
TABLE 7 Europe Biosimilars Market by Country, 2017 - 2020, USD Million
TABLE 8 Europe Biosimilars Market by Country, 2021 - 2027, USD Million
TABLE 9 Europe Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 10 Europe Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 11 Europe Epoetin-alfa Market by Country, 2017 - 2020, USD Million
TABLE 12 Europe Epoetin-alfa Market by Country, 2021 - 2027, USD Million
TABLE 13 Europe Epoetin-beta Market by Country, 2017 - 2020, USD Million
TABLE 14 Europe Epoetin-beta Market by Country, 2021 - 2027, USD Million
TABLE 15 Europe Darbepoetin-alfa Market by Country, 2017 - 2020, USD Million
TABLE 16 Europe Darbepoetin-alfa Market by Country, 2021 - 2027, USD Million
TABLE 17 Europe Other Product Market by Country, 2017 - 2020, USD Million
TABLE 18 Europe Other Product Market by Country, 2021 - 2027, USD Million
TABLE 19 Europe Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 20 Europe Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 21 Europe Renal Diseases Market by Country, 2017 - 2020, USD Million
TABLE 22 Europe Renal Diseases Market by Country, 2021 - 2027, USD Million
TABLE 23 Europe Cancer Market by Country, 2017 - 2020, USD Million
TABLE 24 Europe Cancer Market by Country, 2021 - 2027, USD Million
TABLE 25 Europe Hematology Market by Country, 2017 - 2020, USD Million
TABLE 26 Europe Hematology Market by Country, 2021 - 2027, USD Million
TABLE 27 Europe Neurology Market by Country, 2017 - 2020, USD Million
TABLE 28 Europe Neurology Market by Country, 2021 - 2027, USD Million
TABLE 29 Europe Erythropoietin Drugs Market by Country, 2017 - 2020, USD Million
TABLE 30 Europe Erythropoietin Drugs Market by Country, 2021 - 2027, USD Million
TABLE 31 Germany Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 32 Germany Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 33 Germany Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 34 Germany Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 35 Germany Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 36 Germany Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 37 Germany Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 38 Germany Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 39 UK Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 40 UK Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 41 UK Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 42 UK Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 43 UK Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 44 UK Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 45 UK Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 46 UK Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 47 France Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 48 France Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 49 France Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 50 France Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 51 France Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 52 France Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 53 France Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 54 France Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 55 Russia Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 56 Russia Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 57 Russia Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 58 Russia Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 59 Russia Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 60 Russia Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 61 Russia Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 62 Russia Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 63 Spain Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 64 Spain Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 65 Spain Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 66 Spain Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 67 Spain Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 68 Spain Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 69 Spain Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 70 Spain Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 71 Italy Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 72 Italy Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 73 Italy Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 74 Italy Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 75 Italy Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 76 Italy Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 77 Italy Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 78 Italy Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 79 Rest of Europe Erythropoietin Drugs Market, 2017 - 2020, USD Million
TABLE 80 Rest of Europe Erythropoietin Drugs Market, 2021 - 2027, USD Million
TABLE 81 Rest of Europe Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
TABLE 82 Rest of Europe Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
TABLE 83 Rest of Europe Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
TABLE 84 Rest of Europe Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
TABLE 85 Rest of Europe Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
TABLE 86 Rest of Europe Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
TABLE 87 Key information –Johnson and Johnson
TABLE 88 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 89 Key Information – Amgen, Inc.
TABLE 90 key information – F. Hoffmann-La Roche Ltd.
TABLE 91 Key Information – Biocon Limited
TABLE 92 Key Information – Intas Pharmaceutical Ltd.
TABLE 93 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 94 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 95 Key Information – LG Corporation
TABLE 96 key information – Celltrion, Inc.

List of Figures
FIG 1 Methodology for the research

Purchase Full Report of
Europe Erythropoietin Drugs Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL